167 related articles for article (PubMed ID: 38697678)
1. Efficacy of dual checkpoint inhibitors in a patient with a mixed hepatocellular cholangiocarcinoma.
Sucre S; Bullock A; Peters ML
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38697678
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma.
Jang YJ; Kim EJ; Kim HD; Kim KP; Ryu MH; Park SR; Choi WM; Lee D; Choi J; Shim JH; Kim KM; Lim YS; Lee HC; Ryoo BY; Yoo C
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7547-7555. PubMed ID: 36971796
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
4. [A case of unresectable combined hepatocellular cholangiocarcinoma showing favorable response to LFP therapy].
Kato S; Takeuchi Y; Wada N; Morimoto Y; Kuwaki K; Ohnishi H; Nakamura S; Shiraha H; Takaki A; Okada H
Nihon Shokakibyo Gakkai Zasshi; 2016; 113(12):2050-2056. PubMed ID: 27916773
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.
Tsang J; Wong JSL; Kwok GGW; Li BCW; Leung R; Chiu J; Cheung TT; Yau T
Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):589-598. PubMed ID: 33666530
[TBL] [Abstract][Full Text] [Related]
6. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
Kobayashi S; Terashima T; Shiba S; Yoshida Y; Yamada I; Iwadou S; Horiguchi S; Takahashi H; Suzuki E; Moriguchi M; Tsuji K; Otsuka T; Asagi A; Kojima Y; Takada R; Morizane C; Mizuno N; Ikeda M; Ueno M; Furuse J
Cancer Sci; 2018 Aug; 109(8):2549-2557. PubMed ID: 29856900
[TBL] [Abstract][Full Text] [Related]
7. [Effectiveness of systemic chemotherapy of GEM+CBDCA+5-FU/LV and hepatic arterial infusion of CDDP in a case of advanced, combined hepatocellular-cholangiocarcinoma with multiple lung metastases].
Tani S; Murata S; Tamura M; Fukunaga K; Morita M; Hirata Y; Iida H; Kakuno A; Nishigami T; Yamanaka N
Nihon Shokakibyo Gakkai Zasshi; 2011 Nov; 108(11):1892-901. PubMed ID: 22056711
[TBL] [Abstract][Full Text] [Related]
8. Milestones in the pathogenesis and management of primary liver cancer.
Nault JC; Cheng AL; Sangro B; Llovet JM
J Hepatol; 2020 Feb; 72(2):209-214. PubMed ID: 31954486
[No Abstract] [Full Text] [Related]
9. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas.
Kubicka S; Rudolph KL; Tietze MK; Lorenz M; Manns M
Hepatogastroenterology; 2001; 48(39):783-9. PubMed ID: 11462924
[TBL] [Abstract][Full Text] [Related]
11. Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition.
Swed B; Ryan K; Gandarilla O; Shah MA; Brar G
Medicine (Baltimore); 2021 Jun; 100(25):e26471. PubMed ID: 34160456
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective study.
Gigante E; Bouattour M; Bedoya JU; Regnault H; Ziol M; Assenat E; Paradis V; Calderaro J; Ganne-Carrié N; Bouhier-Leporrier K; Amaddeo G; Nault JC
United European Gastroenterol J; 2024 May; 12(4):429-439. PubMed ID: 38059651
[TBL] [Abstract][Full Text] [Related]
13. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma.
Guion-Dusserre JF; Lorgis V; Vincent J; Bengrine L; Ghiringhelli F
World J Gastroenterol; 2015 Feb; 21(7):2096-101. PubMed ID: 25717243
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
15. Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report.
Marciano R; Servetto A; Bianco C; Bianco R
J Med Case Rep; 2017 Sep; 11(1):273. PubMed ID: 28946921
[TBL] [Abstract][Full Text] [Related]
16. The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study.
Huang P; Huang X; Zhou Y; Yang G; Sun Q; Shi G; Chen Y
Can J Gastroenterol Hepatol; 2022; 2022():9680933. PubMed ID: 36199981
[TBL] [Abstract][Full Text] [Related]
17. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
18. Advanced Cholangiocarcinoma With High Tumor Mutation Burden Achieving Complete Response to Immune Check Point Inhibitor.
Okabe H; Masuda T; Nitta H; Tomita M; Ono A; Kuroda D; Kuroki H; Hirota M; Hibi T; Baba H; Sugita H
Anticancer Res; 2024 Jul; 44(7):3199-3203. PubMed ID: 38925819
[TBL] [Abstract][Full Text] [Related]
19. Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience.
Ghiringhelli F; Lorgis V; Vincent J; Ladoire S; Guiu B
Chemotherapy; 2013; 59(5):354-60. PubMed ID: 24821200
[TBL] [Abstract][Full Text] [Related]
20. Does aspirin use influence hepatocellular carcinoma and cholangiocarcinoma prognosis?
Stefanini B; Tonnini M; Marseglia M; Tovoli F
Expert Rev Anticancer Ther; 2022 Sep; 22(9):887-889. PubMed ID: 35866267
[No Abstract] [Full Text] [Related]
[Next] [New Search]
